VAL-DE-REUIL, France--(BUSINESS WIRE)--ANGANY Genetics, a biotechnology company specialising in the development and production of recombinant allergens for the diagnosis and treatment of allergies, plans to start its new production unit at the PharmaParc II activities park in Val-de-Reuil (Eure) in May. Until now, the company has been using a prototype-scale production facility but the new functional unit will enable industrial-scale production of a series of purified and optimised allergens starting in the second half of the year.
The allergens in question are in particular Der p 1 and Der p 2, which affect 80% of patients with house dust mite allergies, allergens Der p 4 and Der p 7, also for house-mite allergies, and allergens inducing pollen and animal allergies.
